Novavax, Inc.NVAX

Healthcare
Bearish

ASignal's systematic analysis rates NVAX as Bearish. Novavax, Inc. has a market cap of $1.56B, a -14.7% net margin, and -79.1% year-over-year revenue growth.

Reflects the latest available analysis · analyzed Jun 7, 2026

The case on NVAX

Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.

Bull case
  • Positive MACD histogram indicating short-term momentum
  • Current ratio of 2.48x suggests strong liquidity position
  • High cash reserves with $790.33M in total cash
  • Price above 20-day and 50-day moving averages
VS
Bear case
  • Negative revenue growth year-over-year (-79.10%)
  • Negative profit and operating margins
  • Forward P/E of -17.49x indicates unprofitability
  • Negative enterprise value to EBITDA (17.89x) reflects weak earnings base
  • No Reddit mentions, suggesting lack of retail investor interest

Key facts

Sector
Healthcare
Market cap
$1.56B
Gross margin
27.5%
Net margin
-14.7%
Rev growth YoY
-79.1%
Price (Jun 7, 2026)
$9.49
Subscriber-only

See the full verdict on NVAX

ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.

How ASignal analyzes NVAX

Most investors never get a second opinion, let alone several. ASignal runs NVAX past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.

The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.

Novavax, Inc. (NVAX) Stock Analysis - ASignal rates it Bearish